Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firmonertinib versus platinum-based chemotherapy as first-line treatment for EGFR PACC- or L861Q-mutant advanced non-small cell lung cancer
CTR20243831Phase 3Active
- Sponsor
- Allist Pharmaceuticals
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Allist Pharmaceuticals. Started Dec 2024; status: active.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20243831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243831.